Amphetamine-type stimulants. AMPHETAMINE-TYPE SUBSTANCE USE DISORDER
Conditions
Interventions
Intervention 1: Intervention group: This group contains individuals with amphetamine use disorder. Following consenting procedures and randomization, all participants in the experimental group underwe
Sponsors
Self funded
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 40 years age and therefore legally eligible to consent. A history of use of methamphetamine and a diagnosis of stimulant use disorder as described in the Mental Disorders Diagnostic and Statistical Manual (DSM-5); the passage of more than a week from complete methamphetamine detoxification and negative urine test. Be able to speak and read Urdu, sign a written consent for the participants to take part in the study, be mindful. Apart from signing into a written agreement, they have their rights, including the protection of personal data, the immunity to physical or mental harm, and the possibility of quitting the study they wish. All participants would go through urinalysis to make sure that they are not intoxicated
Exclusion criteria
Exclusion criteria: Unwilling to attend the meetings, absenteeism of more than two sessions, engage concurrently in other health services, and have a long-term dependency on multi-drug concurrently; Requisite medical detoxification from any substances Those are suffering from severe medical and neuropsychiatric complications or any psychotic illness at the time of screening for intake Participants those are unavailable or hesitant to be a part of the study for the 20 weeks An individual having a history of using illicit substance use (e.g. cocaine, heroin) Already completed MBRP sessions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure impulsivity in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Barratt Impulsiveness Scale-11.;Craving in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Penn Alcohol Craving Scale (PACS) adopted for methamphetamine.;Aggression in ATS users. Timepoint: Baseline;During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT);3-month follow-up. Method of measurement: Aggression Questionnaire (Buss & Perry, 1992). | — |
Secondary
| Measure | Time frame |
|---|---|
| Self efficacy in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: General Self-Efficacy Scale (GSES).;Coping skills in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Brief COPE inventory (Carver, 1997).;Quality of life in ATS users. Timepoint: Baseline; During Intervention the beginning of week 5 Post-intervention, the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: WHOQOl-BREF (WHO, 1998).;Measuring risk of relapse in ATS users. Timepoint: Baseline; the end of the week (PRIMARY ENDPOINT); a 3-month follow-up. Method of measurement: Stimulant Relapse Risk Scale (SRRS). | — |
Countries
Pakistan
Contacts
Public ContactAftab Hussain
Islamia University Bahawalpur
Outcome results
None listed